Tagged: pharma
30 results
Code Ocean
Code Ocean is a New York-based B2B SaaS platform that makes computational research reproducible, traceable and collaborative. Its flagship Compute Capsule bundles code, data and the exact software environment together so an analysis runs identically today or years from now. Used by pharma, biotech and leading research institutes, and integrated with journals like Nature and IEEE, Code Ocean is building a trusted virtual lab where both scientists and AI agents can run real analyses with full version control, lineage and compliance.
DeepHow
DeepHow is a Detroit-based enterprise AI company that turns the hands-on know-how of experienced industrial workers into structured, searchable training. Founded in 2018 by former Siemens innovation leaders, its platform uses vision AI and machine learning to capture expert workflows on video, automatically segment and transcribe them into step-by-step guides, and - in its newer 'physical AI' products - verify that frontline operators are performing tasks correctly in real time. Used by manufacturers, pharma companies and field-service organizations to close skills gaps as veteran workers retire.
Forus
Forus is a New York-based healthtech company (formerly Tandem Technology, Inc.) that runs an AI-powered network connecting doctors, pharmacies, payers, and biopharma to get prescribed medications to patients faster. Its software embeds in physician workflows and automates the administrative steps between a clinical decision and a patient starting treatment - prior authorization, benefit verification, financial assistance, and pharmacy routing. Free for doctors and patients, Forus earns revenue through pharmaceutical partnerships. Founded in 2023 by former Oscar Health product leader Sahir Jaggi, the company reached a reported $1 billion valuation in May 2026 with backing from Thrive Capital, General Catalyst, and Accel.
Lyfegen
Lyfegen is a Swiss health-tech company that builds software to manage value-based drug pricing and rebate agreements. Its platform helps health insurers, governments, hospital payers, pharmaceutical firms and medical device makers automate complex rebate contracts, run pricing simulations and tap the world's largest library of value-based agreements - reducing administrative burden while helping patients access innovative therapies.
Girisha Fernando
Girisha Fernando is the CEO and co-founder of Lyfegen, a Basel- and Boston-based healthtech company building software that helps payers, hospitals, pharma companies and medical device makers manage value-based drug pricing, access and rebate agreements. After nearly a decade at Roche in market access, pricing and IT, he left in 2018 to build technology that ties the price of medicine to how well it actually works for patients. He splits his time between Switzerland and New York as Lyfegen pushes into the US market.
Paul Eccles
Paul Eccles is a molecular biologist turned healthcare strategy consultant who leads Basis Health, the New York-based life sciences division of London-headquartered insight consultancy Basis Global. He joined Basis in September 2022 as Managing Partner after a career spanning Trinity Life Sciences, BluePrint Research Group, Cello Health, and Opinion Health, and has spent more than fifteen years advising pharma, biotech, and clinical incubators on commercialization, licensing, forecasting, and portfolio positioning.
Sean X. Hu
Sean X. Hu is the President and CEO of Rapafusyn Pharmaceuticals, a Baltimore-based biotech spun out of Johns Hopkins that is building a library of natural-product-like macrocycles it calls RapaGlues. He is a genomics PhD turned Wharton MBA turned management consultant turned operator, with prior stops at Bristol Myers Squibb, CuraGen, Illumina, AT Kearney, IMS, Bionest, BioStrat, GlobalData, and Avotres. In September 2025 he closed an oversubscribed $44M Series A led by BioTrack Capital and Yonjin Capital to push RapaGlues into difficult-to-drug targets.
Cromatic
Cromatic is an AI-native platform for life-science R&D outsourcing and revenue operations. It runs a curated marketplace connecting biotech and pharma companies with vetted Contract Research Organizations (CROs) and Contract Development and Manufacturing Organizations (CDMOs), then layers on vendor discovery, project tracking, data storage, collaboration, contracting, and milestone payments so scientists can outsource complex research without stitching together spreadsheets, email threads, and word-of-mouth referrals. Founded in 2022 by Stanford geneticist Ann Lin and former Meta engineer Anne Chen, the company raised a $5.3M oversubscribed seed round in November 2023 and manages tens of millions of dollars in research budgets.
Delineate
Delineate is a Cambridge, Massachusetts AI company building agents that accelerate clinical trial design for pharmaceutical and biotech companies. Its custom large language models and computer vision systems extract and structure data from thousands of research papers and patents - including numbers buried inside figures and plots - turning months of manual evidence aggregation into weeks. A Y Combinator Winter 2025 company founded in 2024 by an MIT PhD and an ex-Lockheed Skunkworks AI lead, Delineate works with two top-10 pharmaceutical companies and holds an NIH STTR grant with MIT.
Atinary Technologies
Atinary Technologies is a Swiss-American deeptech startup whose no-code SDLabs platform pairs machine learning with lab robotics to run Self-Driving Labs - closed-loop experiments that learn and adapt on the fly, accelerating R&D in chemistry, materials, pharma and climate tech by orders of magnitude.
Synthio Labs
Synthio Labs builds clinical-grade voice and agentic AI for life sciences customer engagement. Its platform helps pharma field teams, medical affairs, and patient-support orgs run compliant, continuous conversations across HCPs and patients, powered by a clinical reasoning engine that ingests FDA labels and real-world evidence.
Dan Cornwell
Dan Cornwell is the founder and CEO of PrescriberPoint, a Boston-based, AI-enabled medication access platform that helps clinicians cut through the paperwork between writing a prescription and a patient actually getting their medicine. Spun out of Eli Lilly in partnership with BCG Digital Ventures, the company raised seed backing from an unusual coalition of would-be rivals - Lilly, Pfizer, Adobe and Mastercard. Before PrescriberPoint, Cornwell ran the nurse-staffing marketplace IntelyCare and advised companies on building disruptive businesses at BCG Digital Ventures. A Yale historian turned Wharton-trained operator, he keeps returning to the same problem: the messy gap between a good intention and a completed transaction.
Dennis X. Hu
Dennis X. Hu is the founder and CEO of Drug Hunter, a subscription knowledge platform that distills the science behind new medicines for more than 200 R&D institutions, including most of the world's top pharma and biotech companies. A medicinal chemist by training, he led small-molecule teams at Genentech and the biotech RAPT Therapeutics (where he helped invent the Phase II oncology candidate tivumecirnon) before turning a side project into a fully remote company of 20+ employees that reaches millions of searches a year and runs entirely on subscription revenue.
PointCross Life Sciences
PointCross Life Sciences is a Foster City, California software and services company that turns the messy data of drug development into FDA-ready submissions. Through its XBIOM platform and eDataValidator, it standardizes nonclinical and clinical study data to CDISC SEND, SDTM and ADaM formats, runs a Hadoop-based data repository for sponsors, and supplies the U.S. FDA itself with the software reviewers use to read nonclinical submissions. The company quietly powers roughly a quarter of all FDA SEND submissions.
Unlearn.AI
Unlearn.AI is a San Francisco biotech-AI company that builds disease-specific machine learning models to generate digital twins of clinical trial participants - longitudinal predictions of how each patient would have fared on placebo. Folded into a statistical method called PROCOVA and a trial design called TwinRCT, the approach lets sponsors shrink control arms by up to a third, so more patients receive the experimental drug while trials reach answers faster. Founded in 2017 by physicists Charles Fisher, Aaron Smith and Jon Walsh, the company has raised about $130M and earned a first-of-its-kind EMA qualification for an AI-based method to reduce sample size in pivotal trials.
Biorce
Biorce is a Barcelona-based healthtech company building AI-native infrastructure for clinical trials. Its core product, Aika, helps pharmaceutical companies, biotechs and CROs design regulator-ready trial protocols in roughly 90 seconds, drawing on a corpus of more than one million clinical studies and 260,000+ protocols. By cutting protocol design time by at least 50% and flagging regulatory and feasibility risks early, Biorce aims to compress the years and billions of dollars it takes to bring a drug to market - so treatments reach patients sooner. In February 2026 it closed a USD $52.5M Series A led by DST Global, the largest Series A to date in the Iberian healthtech and AI ecosystem.
David Steinberg
David Steinberg is Chief Business Officer at Formation Bio, an AI-native pharmaceutical company in New York, where he runs in- and out-licensing and pipeline strategy. A serial biotech company builder, he co-founded PureTech Health and served as its Chief Innovation Officer, was a General Partner at Longwood Fund, and founded or led a string of NASDAQ-listed and venture-backed companies including Pyxis Oncology, Vor Biopharma, Vedanta Biosciences and Be Biopharma. He pairs a Cornell biology degree with a University of Chicago Booth MBA and a career that began in R&D and strategy consulting.
Treeline Biosciences
Treeline Biosciences is a Watertown, Massachusetts biotech founded in 2021 by Loxo Oncology founder Josh Bilenker and former Novartis oncology head Jeff Engelman. It pairs in-house wet-lab R&D with leading-edge computational tools to invent cancer medicines reliably and repeatedly, choosing targets by what the technology can reach rather than by therapeutic fashion. After operating largely in stealth, Treeline has raised more than $1.1 billion and moved three programs - a BCL6 degrader, a pan-KRAS inhibitor, and an EZH2 inhibitor - into Phase 1 trials. In June 2026 it agreed to go public through an all-stock reverse merger with Standard BioTools, with the combined company set to trade on Nasdaq as 'TRLN'.
Vivodyne
Vivodyne is a biotech company that grows more than 20 types of lifelike human organ tissues in the lab, then uses robotic automation to dose, cultivate, and analyze more than 10,000 of them at a time. The vast human datasets it generates feed multimodal AI models that predict how new drugs will behave in people - before they ever reach a clinical trial. The pitch is blunt: roughly 95% of therapies that work in animal models fail in human trials, and Vivodyne wants to fix that gap with real human data instead of mice.
Medisafe
Medisafe is a digital health company that turns the everyday struggle of taking pills on time into a behavior-driven engagement platform. Born from a near-fatal insulin overdose in the founders' own family, it began as a free virtual pillbox app and grew into an enterprise platform - anchored by Medisafe Maestro and its Just-in-Time Interventions (JITI) engine - that pharmaceutical companies use to keep patients on therapy. With more than 13 million users worldwide and 4+ billion doses tracked, Medisafe sits at the intersection of consumer mobile health and the multibillion-dollar problem of medication non-adherence.
Vincent Ling
Vincent Ling is the Chief Business Officer of Morphocell Technologies, a Laval-based regenerative medicine company building iPSC-derived engineered tissues to treat severe organ dysfunction, starting with liver disease. A biotech and pharma veteran of three decades, he spent 12 years at Takeda's Center for External Innovation, where he identified and backed the Kariko-Weissman mRNA platform out of the University of Pennsylvania - the science that became the first COVID mRNA vaccines and earned the 2023 Nobel Prize. He has held leadership roles at Genetics Institute, Adnexus Therapeutics, and Neurotech Pharmaceuticals, and advises the Gates Foundation and academic institutions.
Anthony Costello
Anthony Costello is the CEO of Medidata Solutions, a Dassault Systèmes company, and one of clinical research technology's most seasoned architects. With nearly 30 years in the field, he started as a data manager at Genentech, co-founded two companies (Nextrials and Mytrus), and was acquired by Medidata before rising to lead it. Today he oversees over 8,000 active clinical studies globally each year, championing AI-driven trial innovation, decentralized models, and patient-centric design at the White House Clinical Trials Forum and beyond.
Cellares
Cellares is the first Integrated Development and Manufacturing Organization (IDMO) for cell therapy. Its Cell Shuttle - a fully automated, high-throughput platform roughly the size of a small conference room - replaces a warren of manual labs with one box that can run 16 patient batches in parallel, cutting labor and facility footprint by about 90 percent.
Medable
Medable is a Palo Alto-based digital health company building a cloud SaaS platform for decentralized and hybrid clinical trials. Its tools - eCOA+, Total Consent, Sensors, and Televisit - let pharma sponsors and CROs run studies remotely, enrolling patients in over 60 countries and 120+ languages.
Abhishek Jha
Abhishek Jha is the Co-Founder and CEO of Elucidata, a San Francisco-based AI company making biomedical data AI-ready for drug discovery and pharmaceutical R&D. A trained physical chemist with a PhD from the University of Chicago and postdoctoral work at MIT, he spent years at Agios Pharmaceuticals contributing to four FDA-approved first-in-class therapies before co-founding Elucidata in 2015. Under his leadership, the company has raised over $22.7M in funding, grown to 170 employees, and achieved $22.2M ARR, while evolving from a data-curation platform into an AI company solving out-of-distribution (OOD) problems in biomedical research - work that earned Elucidata recognition as one of Fast Company's Most Innovative Companies in 2024.
Power
Power is a patient-first marketplace for clinical trials. The platform helps patients discover and enroll in promising research studies, while giving sites, sponsors, and CROs an AI-driven engine to accelerate recruitment across 30,000+ active U.S. trials and 10,000+ conditions.
Shahed Jaber
Shahed Jaber is the Co-Founder of Aumet Inc, MENA's largest B2B healthcare procurement marketplace. Based in Riyadh, Saudi Arabia, he previously founded UniOrders - a B2B healthcare marketplace acquired by Aumet in 2020. With a pharmacy background from the University of Jordan, Jaber has helped grow Aumet into an AI-first procurement platform serving 12,000+ pharmacies and 32 hospitals across the MENA region, processing over $1 billion in GMV and raising $21.84M in total funding.
Dan Riskin
Dan Riskin is a physician-entrepreneur, trauma surgeon, and healthcare AI executive who founded Verantos in 2015 to generate high-validity real-world evidence from messy clinical data. A serial innovator who began coding at age 5 and sold software at 12, Riskin holds an MD from Boston University and an MBA from MIT, is board-certified in four specialties, and serves as Clinical Professor of Surgery at Stanford. His prior company Health Fidelity was acquired for more than $150 million. Today, Verantos powers regulatory and reimbursement decisions for major pharmaceutical companies by turning fragmented EHR data into research-grade evidence at scale.
Siva Samy
Dr. Siva Samy is the founder, CEO, and Chief Product Strategist of ValGenesis, the global leader in digital validation lifecycle management for the life sciences industry. He built the first platform to fully digitize and automate the pharmaceutical validation process - the compliance-critical system that ensures every drug, device, and biotech product is manufactured correctly. Under his leadership, ValGenesis has become trusted by 30 of the top 50 global life sciences companies and has raised over $40 million in funding, including a $24M investment from Morgan Stanley Expansion Capital and a $16M debt financing in 2025.
Steve Herne
Steve Herne is the CEO of Unlearn.AI, a San Francisco-based company building AI-powered digital twin technology to transform how clinical trials are designed and run. With over 25 years of experience across pharmaceutical R&D companies including WCG, Bioclinica, and Covance, Herne joined Unlearn in May 2024 as Chief Commercial Officer before ascending to CEO in September 2024. Under his leadership, Unlearn — backed by $130M+ in venture funding including a $50M Series C led by Altimeter Capital — is pivoting from research-led to commercially-driven product delivery, with its digital twin models now EMA-qualified and adopted by major biopharma companies to reduce placebo arm sizes by up to 38% in pivotal trials.